NASDAQ:BMTI - BioMimetic Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company's Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company's product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.

Receive BMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for BMTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:BMTI
CUSIPN/A
Phone+1-615-8441280

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

BioMimetic Therapeutics (NASDAQ:BMTI) Frequently Asked Questions

What is BioMimetic Therapeutics' stock symbol?

BioMimetic Therapeutics trades on the NASDAQ under the ticker symbol "BMTI."

Has BioMimetic Therapeutics been receiving favorable news coverage?

News coverage about BMTI stock has trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioMimetic Therapeutics earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of BioMimetic Therapeutics?

Shares of BMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMimetic Therapeutics' official website?

The official website for BioMimetic Therapeutics is http://biomimetics.com.

How can I contact BioMimetic Therapeutics?

BioMimetic Therapeutics' mailing address is 389 Nichol Mill Lane, FRANKLIN, TN 37067, United States. The biotechnology company can be reached via phone at +1-615-8441280.


MarketBeat Community Rating for BioMimetic Therapeutics (NASDAQ BMTI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about BioMimetic Therapeutics and other stocks. Vote "Outperform" if you believe BMTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel